| http://dbpedia.org/ontology/abstract
|
Crenezumab es un anticuerpo monoclonal que … Crenezumab es un anticuerpo monoclonal que se emplea de forma experimental para el tratamiento de la enfermedad de Alzheimer. Actúa neutralizando la proteína β-amiloide, lo que impiden la agregación de dichas proteínas anómalas, fenómeno que se cree es el desencadenante de la enfermedad. Se están realizando ensayos clínicos con crenezumab para comprobar si es efectivo en el tratamiento y prevención de la enfermedad de Alzheimer.revención de la enfermedad de Alzheimer.
, كرينيزوماب هو جسم مضاد وحيد النسيلة يعمل بالضد من أميلويد بيتا 1-40 و 1-42 لذا فإنه يجرب حالياً ليستخدم في علاج مرض آلزهايمر. كرينيزوماب طورته في البداية شركة دوائية سويسرية تدعى أي سي إميون أس أي والتي سجل اختراعه باسمها، ثم نقلت حقوقه إلى عام 2006.
, Crenezumab is a fully humanized monoclonal … Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.e results of a decade-long clinical trial.
|
| http://dbpedia.org/ontology/casNumber
|
1095207-05-8
|
| http://dbpedia.org/ontology/fdaUniiCode
|
O8AS5277H0
|
| http://dbpedia.org/ontology/kegg
|
D10101
|
| http://dbpedia.org/ontology/wikiPageID
|
33023931
|
| http://dbpedia.org/ontology/wikiPageLength
|
13970
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1124014960
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Colombia +
, http://dbpedia.org/resource/Mini_mental_state_examination +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Humanized_antibody +
, http://dbpedia.org/resource/National_Institutes_of_Health +
, http://dbpedia.org/resource/PSEN1 +
, http://dbpedia.org/resource/Alzheimer%27s_disease +
, http://dbpedia.org/resource/Genentech +
, http://dbpedia.org/resource/Category:Treatment_of_Alzheimer%27s_disease +
, http://dbpedia.org/resource/Solanezumab +
, http://dbpedia.org/resource/Autosomal_dominant +
, http://dbpedia.org/resource/Dietmar_Hopp +
, http://dbpedia.org/resource/Banner_Alzheimer%27s_Institute +
, http://dbpedia.org/resource/Aducanumab +
, http://dbpedia.org/resource/AC_Immune +
, http://dbpedia.org/resource/Initial_public_offering +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/Clinical_trial_phase +
, http://dbpedia.org/resource/Clinical_Dementia_Rating +
, http://dbpedia.org/resource/Early-onset_Alzheimer%27s_disease +
, http://dbpedia.org/resource/Medell%C3%ADn +
, http://dbpedia.org/resource/Beta_amyloid +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/c
|
6442
|
| http://dbpedia.org/property/casNumber
|
1095207
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/h
|
9966
|
| http://dbpedia.org/property/kegg
|
D10101
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1706
|
| http://dbpedia.org/property/o
|
2018
|
| http://dbpedia.org/property/s
|
40
|
| http://dbpedia.org/property/source
|
zu/o
|
| http://dbpedia.org/property/target
|
1
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
O8AS5277H0
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
458433785
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Monoclonals_for_bone%2C_musculoskeletal%2C_circulatory%2C_and_neurologic_systems +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Category:Treatment_of_Alzheimer%27s_disease +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Crenezumab?oldid=1124014960&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Crenezumab +
|
| owl:sameAs |
http://ar.dbpedia.org/resource/%D9%83%D8%B1%D9%8A%D9%86%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8 +
, http://es.dbpedia.org/resource/Crenezumab +
, http://yago-knowledge.org/resource/Crenezumab +
, http://dbpedia.org/resource/Crenezumab +
, http://www.wikidata.org/entity/Q5184156 +
, https://global.dbpedia.org/id/4iR6n +
, http://rdf.freebase.com/ns/m.0h52wn8 +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
كرينيزوماب هو جسم مضاد وحيد النسيلة يعمل بالضد من أميلويد بيتا 1-40 و 1-42 لذا فإنه يجرب حالياً ليستخدم في علاج مرض آلزهايمر. كرينيزوماب طورته في البداية شركة دوائية سويسرية تدعى أي سي إميون أس أي والتي سجل اختراعه باسمها، ثم نقلت حقوقه إلى عام 2006.
, Crenezumab is a fully humanized monoclonal … Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.e results of a decade-long clinical trial.
, Crenezumab es un anticuerpo monoclonal que … Crenezumab es un anticuerpo monoclonal que se emplea de forma experimental para el tratamiento de la enfermedad de Alzheimer. Actúa neutralizando la proteína β-amiloide, lo que impiden la agregación de dichas proteínas anómalas, fenómeno que se cree es el desencadenante de la enfermedad. Se están realizando ensayos clínicos con crenezumab para comprobar si es efectivo en el tratamiento y prevención de la enfermedad de Alzheimer.revención de la enfermedad de Alzheimer.
|
| rdfs:label |
كرينيزوماب
, Crenezumab
|
